Synapse - Martin Tallman

Results (649)

Slit-Robo pathway is clinically relevant and may represent a potential target in acute promyelocytic leukemia

Meeting Abstract

Weinhauser, I.; Pereira-Martins, D. A.; Ortiz, C.; Schiavinato, J. L.; Bonaldo, C.; Koury, L. C.; Wagatsuma, V. M. D.; Melo, R. A. M.; Bittencourt, R.; Pagnano, K. B.; more...
Blood (2018)

Fulltext@MSK | Save

Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy

Meeting Abstract

Talati, C.; Goldberg, A. D.; Przespolewski, A.; Chan, O.; Al Ali, N.; Famulare, C.; Sallman, D. A.; Padron, E.; Kuykendall, A.; List, A. F.; more...
Blood (2018)

Fulltext@MSK | Save

Hematologic malignancies arising in patients with germ cell tumors: Secondary somatic differentiation of hematopoietic malignancies from germ cell precursors

Meeting Abstract

Taylor, J.; Donoghue, M.; Rampal, R. K.; Tamari, R.; Tallman, M. S.; Feldman, D. R.; Taylor, B. S.; Abdel-Wahab, O. I.
Blood (2018)

Fulltext@MSK | Save

Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents

Meeting Abstract

Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
Blood (2018)

Fulltext@MSK | Save

Ratify (Alliance 10603): Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy

Meeting Abstract

Voso, M. T.; Larson, R. A.; Prior, T.; Marcucci, G.; Jones, D.; Krauter, J.; Heuser, M.; Lavorgna, S.; Nomdedeu, J.; Geyer, S. M.; more...
Blood (2018)

Fulltext@MSK | Save

Genomic landscape impacts induction outcome with CPX-351 in patients with acute myeloid leukemia

Meeting Abstract

Talati, C.; Goldberg, A. D.; Desai, P.; Chan, O.; Famulare, C.; Komrokji, R. S.; Kuykendall, A. T.; Fernandez, H. F.; Deutsch, Y. E.; Padron, E.; more...
Blood (2018)

Fulltext@MSK | Save

Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions

Meeting Abstract

Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; more...
Blood (2018)

Fulltext@MSK | Save

A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912)

Meeting Abstract

Shanafelt, T. D.; Wang, V.; Kay, N. E.; Hanson, C. A.; O'Brien, S. M.; Barrientos, J. C.; Erba, H. P.; Stone, R. M.; Litzow, M. R.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save

Prognostic impact of insertion site in acute myeloid leukemia (AML) with FLT3 internal tandem duplication: Results from the ratify study (Alliance 10603)

Meeting Abstract

Rucker, F. G.; Du, L.; Blatte, T. J.; Benner, A.; Krzykalla, J.; Gathmann, I.; Larson, R. A.; Lo-Coco, F.; Amadori, S.; Prior, T. W.; more...
Blood (2018)

Fulltext@MSK | Save

Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant untreated AML: Results from a phase 1 dose escalation and expansion study

Meeting Abstract

Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Donnellan, W. B.; Erba, H. P.; more...
Blood (2018)

Fulltext@MSK | Save

Martin Stuart Tallman

Results (649)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract